Supplementary Tables S1-S9 from Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type

Table S1 shows the cell viability inhibitory rate (%) in SCCOHT cell lines vs other cell lines in the epigenetic drug screen. Table S2 shows the effects of Quisinostat on the proteome of BIN67 cells after treatment for 24 or 72 hours. Table S3 shows the significantly altered proteins by Quisinostat treatment for 24 hours in BIN67 cells. Table S4 shows the significantly altered proteins by Quisinostat treatment for 72 hours in BIN67 cells. Table S5 shows the biological functions that were significantly affected by Quisinostat treatment for 72 hours in BIN67 cells. Table S6 shows the proteins that were significantly regulated by SMARCA4 re-expression in BIN67 cells. Table S7 shows the biological functions that were significantly affected by SMARCA4 re-expression in BIN67 cells. Table S8 shows the proteins that were significantly regulated by both Quisinostat treatment (72 hr) and SMARCA4 re-expression in BIN67 cells. Table S9 shows the biological functions that were significantly affected by both Quisinostat and SMARCA4 re-expression in BIN67 cells.表S1展示了表观遗传药物筛选中，高钙血症型卵巢小细胞癌（SCCOHT）细胞系与其他细胞系的细胞活力抑制率（%）。表S2展示了喹诺司他（Quisinostat）孵育BIN67细胞24小时或72小时后，其蛋白质组的变化特征。表S3展示了BIN67细胞经喹诺司他孵育24小时后，显著差异表达的蛋白质。表S4展示了BIN67细胞经喹诺司他孵育72小时后，显著差异表达的蛋白质。表S5展示了BIN67细胞经喹诺司他孵育72小时后，受到显著影响的生物学功能。表S6展示了BIN67细胞中SMARCA4重新表达后，受其显著调控的蛋白质。表S7展示了BIN67细胞中SMARCA4重新表达后，受到显著影响的生物学功能。表S8展示了同时经72小时喹诺司他孵育与SMARCA4重新表达的BIN67细胞中，受两者共同显著调控的蛋白质。表S9展示了同时经喹诺司他孵育与SMARCA4重新表达的BIN67细胞中，受到显著影响的生物学功能。